EngeneIC is a biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV™ is a first-in-class Cyto-Immunotherapy platform.
Location: Australia, New South Wales, Sydney
Member count: 11-50
Total raised: $10M
Founded date: 2001
Investors 1
| Date | Name | Website |
| - | CHAMP Vent... | champventu... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 06.01.2015 | Series B | $10M | - | finsmes.co... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 06.01.2015 | EnGeneIC C... | EnGeneIC, Ltd., a NYC and Sidn... | Australia ... | - | finsmes.co... |